News

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration…
Read More...

Merck, known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced that the companies have entered into a definitive agreement under which Merck,…
Read More...

Genentech, a member of the Roche Group announced a multi-year strategic research collaboration with NVIDIA that couples Genentech’s artificial intelligence (AI) capabilities, extensive…
Read More...

Chiesi Farmaceutici S.p.A ("Chiesi Group"), an international, research-focused biopharmaceuticals and healthcare group, and Haisco Pharmaceutical Group Co.Ltd (Haisco Pharmaceutical)…
Read More...

AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive,…
Read More...

BeiGene, Ltd. announced that the European Commission (EC) has granted marketing authorization for BRUKINSA (zanubrutinib) in combination with obinutuzumab for the treatment of adult…
Read More...

AstraZeneca launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term…
Read More...

Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs…
Read More...

Versameb AG ("Versameb"), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, announced that the U.S. Food and Drug Administration (FDA)…
Read More...

Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination…
Read More...

LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. announced that they…
Read More...

Astellas Pharma Inc. and Propella Therapeutics, Inc. announced that Astellas, through a US subsidiary, and Propella have entered into a merger agreement pursuant to which Astellas will…
Read More...

Kite, a Gilead Company, and Arcellx, Inc. announced that the companies have expanded their existing collaboration, which was originally announced in December 2022. Kite has exercised…
Read More...

Kesin Pharma Corporation, a pharmaceutical company focused on innovative Specialty brands and Unit Dose formulations, announced that the U.S. Food and Drug Administration (FDA) has…
Read More...

MBrace Therapeutics, Inc. (“MBrace”), a privately-held biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates…
Read More...

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, and Absci Corporation, a generative AI drug creation company, announced a drug discovery partnership…
Read More...

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. and Royalty Pharma plc, announced a collaboration to further accelerate the clinical…
Read More...

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, announced…
Read More...

Telix announces that the first patient has been dosed in the Company’s Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting…
Read More...

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announced the close of a €129 million ($138…
Read More...